BWAY
BrainsWay Ltd.
NASDAQ · Healthcare · Medical - Devices · IL
$14.15
−2.48%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 61.0M | 52.2M | 41.0M | 31.8M | 27.2M |
| Cost of Revenue | 15.1M | 12.8M | 10.4M | 8.3M | 7.1M |
| Gross Profit | 45.9M | 39.4M | 30.6M | 23.5M | 20.0M |
| Operating Expenses | |||||
| R&D Expense | 11.1M | 9.6M | 7.2M | 6.7M | 7.7M |
| SG&A Expense | 27.2M | 25.5M | 22.0M | 21.6M | 25.1M |
| General & Admin Expense | 5.2M | 6.5M | 5.8M | 15.7M | 6.9M |
| Selling & Marketing Expense | 14.8M | 18.9M | 16.2M | 5.9M | 18.2M |
| Other Expenses | — | — | — | 133.0K | — |
| Total Operating Expenses | 38.3M | 35.1M | 29.2M | 28.4M | 32.7M |
| Cost and Expenses | 53.4M | 47.9M | 39.6M | 36.7M | 39.9M |
| Operating Income (EBIT) | 7.6M | 4.3M | 1.4M | (5.0M) | (12.7M) |
| Non-Operating | |||||
| Interest Income | 4.3M | 5.6M | 2.5M | 2.2M | 1.1M |
| Interest Expense | 2.2M | 2.2M | 1.4M | 298.0K | 68.0K |
| Net Interest Income | 2.1M | 3.4M | 1.1M | 1.9M | 1.0M |
| Other Non-Op Income/Expense | 2.1M | 3.4M | 2.1M | 1.0M | (351.0K) |
| Non-Operating Income (excl Interest) | (2.9M) | (5.6M) | (2.2M) | (1.1M) | 305.0K |
| EBT (Pre-Tax Income) | 9.7M | 7.7M | 3.5M | (3.9M) | (13.0M) |
| Income Tax Expense | 181.6K | 77.0K | 538.0K | 251.0K | 315.0K |
| Bottom Line | |||||
| Net Income | 9.5M | 7.6M | 2.9M | (4.2M) | (13.3M) |
| Earnings from Cont. Ops | 9.5M | 7.6M | 2.9M | (4.2M) | (13.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 9.5M | 7.6M | 2.9M | (4.2M) | (13.3M) |
| Per Share | |||||
| Basic EPS | $0.46 | $0.40 | $0.09 | ($0.13) | ($0.43) |
| Diluted EPS | $0.44 | $0.36 | $0.09 | ($0.13) | ($0.43) |
| Revenue Per Share | $3.04 | $2.74 | $1.21 | $0.96 | $0.82 |
| Shares | |||||
| Basic Shares Outstanding | 20.1M | 19.1M | 34.0M | 33.2M | 33.0M |
| Diluted Shares Outstanding | 20.1M | 21.2M | 34.8M | 33.2M | 33.0M |
| Profitability Metrics | |||||
| EBITDA | 12.2M | 11.5M | 5.4M | (2.6M) | (11.5M) |
| D&A | 1.7M | 1.5M | 1.8M | 1.3M | 1.5M |
| EBIT | 10.5M | 9.9M | 3.6M | (3.9M) | (13.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026